BPD and the Role of Medication

Borderline personality disorder is one of the most misunderstood and most undertreated psychiatric conditions. Despite its prevalence, it carries a significant stigma, even within clinical settings, which can delay diagnosis and discourage people from seeking care.

And while there is no FDA-approved medication specifically for BPD, unlike conditions such as depression or bipolar disorder, which have dedicated pharmacological treatments, BPD does not. The gold standard of treatment remains psychotherapy, specifically dialectical behavior therapy, which has the strongest evidence base of any treatment for the disorder. Mentalization-based therapy and schema therapy are also well-supported approaches.

That said, medication is routinely used in clinical practice not to treat BPD itself but to target specific symptoms that cause the most distress: mood instability, anger and aggression, impulsivity, anxiety, and depression. When carefully chosen and monitored, the right medications can meaningfully reduce suffering and make it easier for a person to engage with and benefit from therapy.

Below is a symptom-by-symptom guide to medication classes that clinicians commonly utilize in treating BPD, along with relevant research findings.

Mood Instability

Two medication classes are most commonly used to treat BPD mood instability: mood stabilizers and second-generation antipsychotics.

Mood stabilizers such as lamotrigine (Lamictal), valproate (Depakote), and topiramate have shown promise. A randomized controlled trial published in the Journal of Clinical Psychiatry found that lamotrigine significantly reduced impulsivity and, to a lesser degree, emotional instability in patients with BPD. Topiramate has shown similar effects: a double-blind placebo-controlled study demonstrated notable reductions in anger and interpersonal sensitivity among women with BPD treated with topiramate.

Among antipsychotics, aripiprazole (Abilify) and olanzapine (Zyprexa) have the most research support for BPD symptom reduction. A 2007 randomized controlled trial by Nickel and colleagues found that aripiprazole significantly reduced depressive symptoms, anxiety, anger, and overall BPD severity compared to placebo over eight weeks. Olanzapine has shown similar results in multiple trials, though its side effects, including weight gain and elevated blood sugar, require monitoring.

Anger and Aggression

Explosive anger can devastate relationships and generate enormous shame for those who experience it. It is one of the nine diagnostic criteria for BPD and one of the symptoms most responsive to targeted medication.

The previously mentioned topiramate trial, led by Nickel and published in the American Journal of Psychiatry, reported a 50% or greater reduction in anger scores (measured on the State-Trait Anger Expression Inventory) in participants receiving the medication compared to those on placebo. This is a significant and meaningful reduction.

Mood stabilizers like valproate have also demonstrated anger-reducing properties, however they come with a higher risk profile, including liver toxicity. Low-dose antipsychotics may also be used adjunctively when anger is a dominant concern.

Impulsivity and Self-Destructive Behavior

Impulsivity in BPD can manifest in many ways, including reckless spending, substance use, unsafe sexual behavior, binge eating, or self-harm. These behaviors are often attempts to regulate unbearable emotional pain.

SSRIs have been used to treat impulsivity in people with BPD in the past, but the evidence is mixed. A Cochrane systematic review of drug treatments for BPD found that SSRIs showed limited benefit for impulsivity specifically in BPD patients, though they may help with co-occurring depression and anxiety.

More consistent evidence exists for mood stabilizers. Lamotrigine and valproate have both shown impulsivity-reducing effects in controlled trials. In addition, omega-3 fatty acids have also been studied with surprisingly positive results: a small but well- designed randomized controlled trial published in the American Journal of Psychiatry found that omega-3s reduced aggression and depressive symptoms in women with BPD.

Anxiety

Anxiety is a pervasive symptom in BPD; it may present as generalized worry, social anxiety, fears of abandonment, or near-constant hypervigilance. SSRIs and SNRIs (serotonin-norepinephrine reuptake inhibitors) are typically first-line for anxiety and offer modest benefit in BPD patients with prominent anxiety features. Buspirone, a non-habit-forming anxiolytic, is also sometimes used, though evidence specific to BPD is limited.

Benzodiazepines (such as Xanax, Valium, or Klonopin) are generally discouraged in BPD. While they provide fast relief for anxiety, they carry significant risks of dependence and, in some studies, have been associated with paradoxical emotional disinhibition and increased impulsivity in this population. If benzodiazepines are prescribed, careful monitoring is essential.

Depression

Depression in BPD often has a different quality than major depressive disorder: it tends to be more reactive and more tied to interpersonal events. This distinction matters when evaluating medication response.

SSRIs are commonly prescribed and may help with the depressive overlay of BPD, particularly when major depression co-occurs. Fluoxetine (Prozac) has been among the most studied. A placebo-controlled trial by Salzman and colleagues found that fluoxetine reduced anger and depression scores in patients with BPD.

MAOIs (monoamine oxidase inhibitors) showed some early promise in BPD research, particularly for rejection sensitivity and atypical depressive features, but their dietary restrictions and interaction risks make them a last-line option in most clinical settings.

Medication, when thoughtfully selected, can be a valuable part of a comprehensive treatment plan for BPD, but it is never the whole plan. The research is clear: psychotherapy, especially DBT, produces the most lasting gains, while medication can quiet the symptoms.

Source Material: Psychiatryonline.org, ncbi.nlm.nih.gov, cochrane.org, sagepub.com